United States AI in Drug Discovery and Development Market 2033 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Global AI in drug discovery and development market reached US$ 6.24 billion in 2024 and is expected to reach US$ 34.05 billion by 2033, growing at a CAGR of 18.5% during the forecast period 2025-2033.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/ai-in-drug-discovery-and-development-market?sb

Key Development:

United States & Global: Recent AI‐Driven Drug Discovery Developments

✅ In November 2025, Insilico Medicine entered into a collaboration with Eli Lilly & Company, combining Insilico's generative‐AI platform with Lilly's expertise to jointly discover and advance candidate compounds a deal involving > $100 million upfront, milestones, and royalties.

✅ In November 2025, the new generative‐AI model FRAGMENTA was introduced: using a fragment-based generative approach with "agentic tuning," it optimized lead compounds for cancer drug discovery identifying nearly twice as many high‐scoring molecules than baseline methods.

✅ In November 2025, researchers published MADD (Multi‐Agent Drug Discovery Orchestra), a multi‐agent AI system that builds and executes custom hit‐identification pipelines from natural-language queries streamlining de novo compound generation and screening.

✅ In November 2025, Merck KGaA struck a collaboration (potentially worth > $3 billion) with Valo Health a biotech leveraging AI and large patient data sets to develop novel treatments for Parkinson's and related diseases, reflecting growing big‐pharma interest in AI‐enabled discovery.

✅ In November 2025, biotech leaders at the Axios BFD Summit emphasised that AI is now integral across drug‐development pipelines: from gene-driven disease screening to improving R&D efficiency underscoring industry‐wide commitment to AI adoption.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=ai-in-drug-discovery-and-development-market

✅ In November 2025, a biotech startup from Australia Gelomics announced use of AI to grow human‐like tissue models (organoids) to reduce reliance on animal testing, potentially transforming preclinical drug‐discovery stages globally.

✅ In October 2025, Insilico Medicine announced that at the upcoming international conference (BIO‐Europe 2025) it will showcase its AI‐powered drug‐discovery platform alongside a new cardiometabolic drug portfolio highlighting global ambitions for AI‐driven therapeutic development.

✅ In October 2025, a new generative‐AI approach titled Pharmacophore‐Guided Generative Design was published: it balances pharmacophore similarity to known active molecules with structural novelty, generating novel drug‐like compounds (e.g., for estrogen‐receptor modulators).

Key Players:

=> Alphabet (Google DeepMind), Atomwise Inc., BenevolentAI, BioMap, BioSymetrics, DEEP Genomics, Euretos, Exscientia, IBM, and Iktos. Among others.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/ai-in-drug-discovery-and-development-market?sb

Key Segments:

By Technology

Machine Learning leads with 40% share, driven by predictive modeling, pattern recognition, and high-throughput data analysis across drug discovery pipelines. Natural Language Processing (NLP) accounts for 25%, supported by its ability to mine biomedical literature, patents, and clinical records for insights and target identification. Generative AI holds 20%, fueled by molecule generation, de novo drug design, and optimization of chemical structures. Other AI technologies make up 15%, including hybrid and emerging approaches integrating multi-omics data and computational biology platforms. Adoption is accelerated by reduced drug development timelines and cost efficiencies offered by AI-driven workflows.

By Application

Target Discovery & Validation dominates with 20% share, supported by AI's ability to predict novel targets and assess disease pathways. Hit Discovery & Virtual Screening holds 18%, reflecting in silico screening of large chemical libraries. Hit-to-Lead and Lead Optimization account for 15% and 12%, respectively, driven by AI-guided structure-activity relationship predictions and chemical property optimization. Pre-Clinical Testing represents 10%, Clinical Trials 15%, and other applications 10%, highlighting AI integration across the full drug discovery lifecycle from early discovery to clinical development.

By Region

North America - 35% Share
North America leads with 35%, driven by strong pharmaceutical R&D infrastructure, AI adoption in biotech, and supportive regulatory frameworks in the U.S. and Canada.

Europe - 25% Share
Europe holds 25%, supported by AI integration in life sciences, government-backed innovation hubs, and robust pharma and biotech sectors in Germany, U.K., France, Italy, Spain, and neighboring countries.

Asia-Pacific - 25% Share
Asia-Pacific accounts for 25%, fueled by expanding pharmaceutical R&D, growing biotech startups, and AI adoption in China, India, Japan, South Korea, and Southeast Asia.

South America - 7% Share
South America holds 7%, driven by growing pharmaceutical and biotech activities in Brazil, Argentina, and surrounding countries, supported by collaborative AI projects with global pharma.

Middle East & Africa - 8% Share
The Middle East & Africa represent 8%, supported by emerging biotech clusters, government investments in AI healthcare solutions, and early-stage AI-driven drug discovery initiatives in GCC countries, South Africa, and other regions.

FAQ

What is the current size of the AI in drug discovery and development Market?

A: In 2024, the AI in drug discovery and development Market was valued at US$ 6.24 billion, reflecting its strong industry presence.

Q2: How large is the AI in drug discovery and development Market expected to be by 2033?

A: By 2033, industry forecasts suggest the AI in drug discovery and development Market will grow to around US$ 34.05 billion, demonstrating significant expansion.

Q3: What is the growth rate of the AI in drug discovery and development Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 18.5% during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.